Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P0C7V7
UPID:
SC11B_HUMAN
Alternative names:
SEC11 homolog B; SEC11-like protein 2
Alternative UPACC:
P0C7V7
Background:
The Putative signal peptidase complex catalytic subunit SEC11B, also known as SEC11 homolog B and SEC11-like protein 2, plays a crucial role in protein synthesis. It is a putative component of a signal peptidase complex that removes signal peptides from nascent proteins during their translocation into the lumen of the endoplasmic reticulum.
Therapeutic significance:
Understanding the role of Putative signal peptidase complex catalytic subunit SEC11B could open doors to potential therapeutic strategies.